Special Issue

New Advances in Clinical and Translational Breast Cancer Research

Message from the Guest Editors

Despite significant improvements in breast cancer management and prognosis in recent decades, it remains the most common cancer and the leading cause of cancer-related death in women worldwide.

In addition to clinical studies, translational research—which utilises clinical samples and data for discovery and validation studies, and/or seeks to answer specific clinical questions—will be essential in addressing these needs and, crucially, bringing novel findings or emerging treatments closer to the clinic.

In this Special Issue, we will collect original research articles and reviews that report on or summarise the latest findings in clinical and translational breast cancer research. Such studies can lead to the identification or validation of novel biomarkers or potential therapeutic targets, the characterisation of the effects of emerging therapeutics or the development of predictive tools with clinical potential. Additionally, the study of clinical specimens can help shed light on the complexity of the disease, both identifying disease mechanisms or corroborating findings based on pre-clinical cancer models.

Guest Editors

Dr. Carlos Martínez-Pérez
Institute of Genetics and Cancer, Western General Hospital, University of Edinburgh, Edinburgh EH4 2XU, UK

Dr. Arran K. Turnbull
Institute of Genetics and Cancer, Western General Hospital, University of Edinburgh, Edinburgh EH4 2XU, UK

Deadline for manuscript submissions

closed (31 August 2023)

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:
indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:
CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).